Posted by Michael Wonder on 02 Nov 2020
Takeda price hikes for a GI drug may give some patients another kind of stomachache
2 November 2020 - Two weeks ago, Takeda Pharmaceuticals raised the list price of its Entyvio treatment for ulcerative colitis and Crohn’s disease by 4%, to nearly $7,000 for a vial.
This followed an earlier 4% price hike last January, which means the company boosted the list price for its medicine by 8% this year.
